Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of belumosudil (brand name- REZUROCK®) on the background of standard immunosuppression will prevent fibrosis in the kidney transplant. Interstitial expansion is the precursor of interstitial fibrosis and graft loss. The hypothesis underlying the study is that abgrogating the fibrogenic effects of the RhoA pathway with belumosudil will reduce structural damage in transplanted kidneys and possible subsequent transplant failure.

NCT Number	NCT06751602
Lead Sponsor	The Methodist Hospital Research Institute
Conditions	Rejection Chronic Renal
Enrollment	40 participants
Start Date	2025-09-11
Primary Completion	2027-12 (estimated)
Study Completion	2028-03-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-12